Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 3 6Phase 1/2 5Phase 1 4Phase 2/3 1

Status

Terminated 4Unknown 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 5

Conditions

Glioblastoma 5Neoplasms 2Recurrence 1Brain Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 135Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Bevacizumab 95Cyclophosphamide 93Dexamethasone 78Injections 75Docetaxel 72Pemetrexed 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 60130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 56Ipilimumab 54fludarabine 47Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × Lomustine × Clear all
NCT03382977 2026-05-08

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

VBI Vaccines Inc.

Phase 1/2 Terminated
70 enrolled
CNS

Glioblastoma, Neoplasms

NCT04421378 2024-12-16

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Karyopharm Therapeutics Inc

Phase 1/2 Terminated
74 enrolled 23 charts
CNS

Glioblastoma

NCT04573192 2024-04-08

GLIOSTAR

Philogen S.p.A.

Phase 1/2 Unknown
142 enrolled
CNS

Glioblastoma

NCT02765165 2021-07-23

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Proximagen, LLC

Phase 1/2 Terminated
26 enrolled 20 charts
CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence

NCT00948389 2012-08-31

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Bristol-Myers Squibb

Phase 1/2 Terminated
28 enrolled 16 charts
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡